Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Common Equity (2016 - 2025)

Historic Common Equity for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to -$264.2 million.

  • Ironwood Pharmaceuticals' Common Equity rose 1515.32% to -$264.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$264.2 million, marking a year-over-year increase of 1515.32%. This contributed to the annual value of -$301.3 million for FY2024, which is 1298.32% up from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Common Equity of -$264.2 million as of Q3 2025, which was up 1515.32% from -$308.2 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' Common Equity's 5-year high stood at $706.9 million during Q1 2023, with a 5-year trough of -$346.8 million in Q2 2023.
  • Moreover, its 5-year median value for Common Equity was -$264.2 million (2025), whereas its average is $85.2 million.
  • In the last 5 years, Ironwood Pharmaceuticals' Common Equity skyrocketed by 972284.89% in 2021 and then crashed by 16507.56% in 2023.
  • Over the past 5 years, Ironwood Pharmaceuticals' Common Equity (Quarter) stood at $605.9 million in 2021, then increased by 7.67% to $652.4 million in 2022, then tumbled by 153.08% to -$346.3 million in 2023, then increased by 12.98% to -$301.3 million in 2024, then increased by 12.34% to -$264.2 million in 2025.
  • Its Common Equity was -$264.2 million in Q3 2025, compared to -$308.2 million in Q2 2025 and -$334.1 million in Q1 2025.